Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study

Annals of Oncology

Volumn 10, Issue 2, 1999, Pages 217-221

  Lippe, P ^c   Tummarello, D ^c   Monterubbianesi, M C ^c   Silva, R R ^a   Giuliodori, L ^a   Mari, D ^c   Santo, A ^c   Pasini, F ^c   Getto, G L ^c   Rossi, D ^a   Porfiri, E ^c   Cascinu, S ^a   Cellerino, R ^b  

^a Medical Oncology Unit   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NONE

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; NSCLC; Weekly administration

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032995550     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008323604269     Document Type: Article

References (24)

1. Cancer Facts and Figures. American Cancer Society 1996.
2. Shepherd FA. Future directions in the treatment of non-small-cell lung cancer. Department of Medicine, Toronto Hospital, Ontario, Canada. Semin Oncol 1994; 21 (Suppl 4): 48-62.
3. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
4. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993; 11: 1866-72.
5. Fossella FV, Lippmann SM, Shin DM et al. Maximum tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small lung cancer. J Clin Oncol 1997; 15: 310-6.
6. Le Chevalier T. Single-agent activity of gemcitabine in advanced non-small-cell lung cancer. Semin Oncol 1996; 23 (Suppl 10): 36-42.
7. Peters GJ, Bergman AM, Ruiz van Haperen VWT et al. Interactions between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (Suppl 11): 72-9.
8. Crinò L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
9. Steward WP, Dunlop DJ, Dabouis G et al. Phase I II study of gemcitabine and cisplalin in the treatment of non-small-cell lung cancer: Preliminary results. Semin Oncol 1996; 23 (Suppl 10): 43-7.
10. Abratt RP, Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9.
11. Anton A, Artal A, Carrato A et al. Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1656).
12. Shepherd Fa, Cormier Y, Burkes R et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 1997; 24 (Suppl 8): 27-30.
13. Einhorn LH. Phase II trial of gemcitabine plus cisplatin in non-small-cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 1997; 24 (Suppl 8): 24-6.
14. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Co-operative Oncology Group study. J Clin Oncol 1986; 4: 702-9.
15. Bakowski MT, Crouch JC. Chemotherapy for non-small-cell lung cancer. A reappraisal and look to the future. Cancer Treat Rev 1983; 10: 159-72.
16. Hardly JR, Noble T Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin C. vinblastine and cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 1989; 60: 764-6.
17. Tummarello D, Graziano F, Isidori P et al. Symptomatic, stage IV, non-small-cell-lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995; 35: 249-53.
18. Gralla R, Casper E, Kelsen D. Cisplatin plus vindesine combination chemotherapy for advanced carcinoma of the lung: A randomised trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414-20.
19. Klastersky J, Sculier J, Ravez P et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4: 1780.
20. Gandara DR, Crowley J, Livingston RB et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11: 873.
21. Vogl SE, Berenzweig M, Camacho F et al. Efficacy study of intensive cisplatin therapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982; 50: 24-6.
22. Wilke H, Achterrath W, Gunzer U et al. Etoposide and split-dose cisplatin therapy in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1986; 5: 179 (Abstr).
23. 2) in non-small-cell lung cancer: Reduced toxicity of a modified dose schedule. Proc Am Soc Clin Oncol 1986; 5: 173 (Abstr).
24. Shepherd FA, Anglin G, Abratt R et al. Influence of gemcitabine (GEM) and cisplatin (CP) schedule on response and survival in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17 (Abstr 1814).